# Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies

Source: https://onco.cc/trials/nct04521413/  
OnCo record `nct04521413` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by Treadwell Therapeutics, Inc, active and no longer recruiting.

## Summary

Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies is a phase 1/2 interventional study registered as NCT04521413 by Treadwell Therapeutics, Inc, with 170 participants enrolled, started 2020-08-31 and due to reach its primary completion in 2025-11. Interventions recorded: CFI-402411 and Pembrolizumab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04521413
- Phase: 1/2
- Setting: A First-In-Human, Phase 1/2 Study Of CFI-402411, a Hematopoietic Progenitor Kinase-1 (HPK1) Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Malignancies
- Sponsor: Treadwell Therapeutics, Inc
- Enrolled: 170

## Sources

- ClinicalTrials.gov NCT04521413: https://clinicaltrials.gov/study/NCT04521413

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Treadwell Therapeutics](https://onco.cc/companies/treadwell-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct04521413.json